Business Context and Reporting Period
Company: IceCure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025
Filing Date: August 13, 2025
This filing incorporates the Company's Unaudited Interim Condensed Consolidated Financial Statements, Management's Discussion and Analysis (MD&A), and a press release regarding financial and operational results for the first half of 2025.
Key Financial Metrics
The provided text serves as a cover sheet and table of contents for the Form 6-K. It references the financial data contained in attached Exhibits 99.1 and 99.2 but does not explicitly state the numerical values within this document.
- Revenue: Not provided in the cover text; see Exhibit 99.1.
- Profit/Loss: Not provided in the cover text; see Exhibit 99.1.
- Cash Flow: Not provided in the cover text; see Exhibit 99.1.
- Margins: Not provided in the cover text; see Exhibit 99.2.
- Debt and Liquidity: Not provided in the cover text; see Exhibit 99.1.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus the prior period. Such analysis is located in the attached Management's Discussion and Analysis (Exhibit 99.2).
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.3) titled "IceCure Reports Financial & Operational Results for the First Half of 2025," which likely contains management commentary and outlook. However, the specific guidance, risks, contingencies, or unusual items are not detailed in the provided cover sheet text.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific values of revenue, net loss, cash position, and liquidity metrics for the six months ended June 30, 2025.
- Consult Exhibit 99.2 (MD&A) to understand the reasons behind financial performance and any material changes from the prior year.
- Read Exhibit 99.3 (Press Release) for management's operational updates, future guidance, and strategic outlook.
- Verify the incorporation by reference of this report into the Company's active Registration Statements on Form F-3 and Form S-8.